Literature DB >> 6185565

Relapsing murine experimental allergic encephalomyelitis induced by myelin basic protein.

R B Fritz, C H Chou, D E McFarlin.   

Abstract

Experimental allergic encephalomyelitis (EAE), an experimental autoimmune disease of the central nervous system (CNS), is readily induced in many mammalian species by immunization with CNS tissue or myelin basic protein (MBP) purified from the CNS. EAE has been frequently used as a model for multiple sclerosis (MS). However, EAE generally presents as an acute monophasic disease in the adult animal after immunization with MBP. After recovery, the animal is resistant to rechallenge with encephalitogen (1). Two exceptions to these observations have been reported. McFarlin et al. (2) reported that a variable number of Lewis rats showed signs of a single, mild relapse about a week after recovery from MBP-induced acute EAE. Panitch and Ciccone (3) have reported induction of recurrent EAE in rats immunized with human MBP. Chronic, relapsing EAE has been induced in the mouse; however, an apparent requirement for CNS tissue had been noted (4, 5). Recently, during the course of a series of experiments on the induction of EAE in SJL/J, PL/J, and (SJL/J X PL/J)F1 (SPL F1) mice, it was observed that the F1 mice frequently had paralytic relapses after recovery from MBP-induced symptoms. Experiments were initiated to examine this phenomenon, and the findings are presented below.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6185565

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

1.  T cell-independent rescue of B lymphocytes from peripheral immune tolerance.

Authors:  V Kouskoff; G Lacaud; D Nemazee
Journal:  Science       Date:  2000-03-31       Impact factor: 47.728

Review 2.  Multiple sclerosis and its animal models: the role of the major histocompatibility complex and the T cell receptor repertoire.

Authors:  L Steinman
Journal:  Springer Semin Immunopathol       Date:  1992

3.  Antigen-specific therapy of experimental allergic encephalomyelitis by soluble class II major histocompatibility complex-peptide complexes.

Authors:  S D Sharma; B Nag; X M Su; D Green; E Spack; B R Clark; S Sriram
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

4.  Ophthalmopathology in rats with MBP-induced experimental autoimmune encephalomyelitis.

Authors:  Oliver W Gramlich; Stephanie C Joachim; Philip F Gottschling; Panagoitis Laspas; Clemens S Cuny; Norbert Pfeiffer; Franz H Grus
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-02-23       Impact factor: 3.117

5.  Clonal diversity of myelin basic protein-specific T lymphocytes.

Authors:  S K Huang; S Sriram
Journal:  Immunogenetics       Date:  1988       Impact factor: 2.846

6.  Experimental Autoimmune Encephalomyelitis.

Authors:  Clara Ballerini
Journal:  Methods Mol Biol       Date:  2021

7.  Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation.

Authors:  D M Karussis; U Vourka-Karussis; D Lehmann; H Ovadia; R Mizrachi-Koll; A Ben-Nun; O Abramsky; S Slavin
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

8.  Accelerated induction of experimental allergic encephalomyelitis in PL/J mice by a non-V beta 8-specific superantigen.

Authors:  J M Soos; A C Hobeika; E J Butfiloski; J Schiffenbauer; H M Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-20       Impact factor: 11.205

9.  Acute experimental allergic encephalomyelitis in radiation bone marrow chimeras between high and low susceptible strains of mice.

Authors:  R Korngold; A Feldman; L B Rorke; F D Lublin; P C Doherty
Journal:  Immunogenetics       Date:  1986       Impact factor: 2.846

10.  Delayed-type hypersensitivity to myelin basic proteins in mice susceptible to allergic encephalomyelitis.

Authors:  D S Linthicum; G A Hashim
Journal:  Neurochem Res       Date:  1984-10       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.